A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies.
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Transgene
- 入组人数
- 143
- 试验地点
- 21
- 主要终点
- Phase Ib: To Evaluate the Safety and Tolerability of the Combination of TG4001 Plus Avelumab in Participants With Recurrent or Metastatic HPV-16 Positive Advanced Malignancies
研究概览
简要总结
The study will consist of two parts :
In the phase Ib: safety will be assessed in consecutive cohorts of 3 to 6 participants at increasing doses of TG4001 in combination with avelumab according to a 3+3 design. There will be no intra-participant dose escalation.
In the phase II part 1, evaluation of efficacy and further evaluation of safety of the combination of TG4001 and avelumab will be performed in a single arm of participants with recurrent or metastatic HPV-16 positive advanced malignancies.
In the phase II part 2, evaluation of efficacy of the combination of TG4001 and avelumab will be performed in a randomized, open-label controlled study comparing TG4001 in combination with avelumab to avelumab alone in participants with HPV-16 positive advanced malignancies.
In both phases, evaluation of tumor response will be done locally according to RECIST 1.1.
All participants will be followed up until disease progression, death, or unacceptable toxicity, or study withdrawal for any reason, whichever occurs first.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female or male participants, aged at least 18 years (no upper limit of age)
- •ECOG PS 0 or 1
- •Life expectancy of at least 3 months
- •Participants with histologically or cytologically documented metastatic or refractory/recurrent HPV-16 + cancer: cervical, vulvar, vaginal, penile and anal.
- •Disease MUST not be amenable to curative surgery resection or curative radiotherapy with documented disease progression
- •Prior therapy:
- •No more than one prior systemic treatment for recurrent /metastatic disease
- •Prior treatment for recurrent or metastatic disease is not required for:
- •Participants with recurrence/progression within 6 months after completion of prior multimodal therapy for localized or locally advanced disease
- •Participants who are unsuitable for platinum-based therapy
- •Participants who refuse chemotherapy or other standard therapies for the treatment of metastatic or recurrent disease
- •Limited hepatic disease for participants with liver metastases at baseline
- •Availability of tumor tissue from biopsy
- •At least one measurable lesion by CT scan according to RECIST 1.
- •Adequate hematological, hepatic and renal function
- •Negative blood pregnancy test at screening for women of childbearing potential
- •Highly effective contraception for both male and female participants if the risk of conception exists during the study period and for 3 months after the last study treatment administration
排除标准
- •Prior exposure to cancer immunotherapy including cancer vaccines, any antibody/drug targeting T cell co-regulatory proteins (immune checkpoints)
- •Participants under chronic treatment with systemic corticosteroids or other immunosuppressive drugs for a period of at least 4 weeks and whose treatment was not stopped 2 weeks prior to the first study treatment, with the exception of participants with adrenal insufficiency who may continue corticosteroids at physiological replacement dose, equivalent to ≤ 10 mg prednisone daily. Steroids with no or minimal systemic effect (topical, inhalation) are allowed
- •Participants with CNS metastases except those with brain metastases treated locally and clinically stable during 4 weeks prior to start of study treatment, and those without ongoing neurological symptoms that are related to the brain localization of the disease
- •Other active malignancy requiring concurrent systemic intervention
- •Participants with previous malignancies other than the target malignancy to be investigated in this trial (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period
- •Participant with any organ transplantation, including allogeneic stem cell transplantation
- •Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 NCI-CTC), any history of anaphylaxis, or uncontrolled asthma
- •Any known allergy or reaction to eggs, gentamycin or attributed to compounds of similar chemical or biological composition to therapeutic vaccines/immunotherapeutic products
- •Any known allergy or reaction to any component of anti-PD-L1/PD-1 or its excipients
- •Participants with known history or any evidence of active interstitial lung disease / pneumonitis
- •Participants with active, known, or suspected auto-immune disease or immunodeficiency, except type I diabetes mellitus, hypothyroidism only requiring hormone replacement or skin disorders (such as vitiligo, psoriasis) not requiring systemic treatment
- •Clinically significant (that is, active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction (< 6 months prior to enrollment), unstable angina pectoris, congestive heart failure (New York Heart Association Classification Class ≥ II), or serious uncontrolled cardiac arrhythmia requiring medication/active intervention, history of myocarditis
- •History of uncontrolled intercurrent illness including but not limited to:
- •Hypertension uncontrolled by standard therapies (not stabilized to 150/90 mmHg or lower)
- •Uncontrolled diabetes (e.g., hemoglobin A1c ≥ 8%)
- •Uncontrolled infection
研究组 & 干预措施
TG4001/Avelumab
干预措施: TG4001 (Biological)
TG4001/Avelumab
干预措施: Avelumab (Drug)
Avelumab
Applicable for Phase II part 2.
干预措施: Avelumab (Drug)
结局指标
主要结局
Phase Ib: To Evaluate the Safety and Tolerability of the Combination of TG4001 Plus Avelumab in Participants With Recurrent or Metastatic HPV-16 Positive Advanced Malignancies
时间窗: From Day 1 to Day 28
Dose limiting toxicities (DLTs) includes the following: * Grade ≥ 3 drug related adverse event (AEs). However, fatigue, nausea/vomiting adequately treated with anti-emetics, endocrinopathies adequately controlled with one physiologic hormone replacement, skin toxicity and single laboratory values out of normal range without any clinical correlate, asymptomatic grade ≥3 lipase or amylase elevation, tumor flare defined as local pain, irritation, or rash localized at sites of known or suspected tumor or a transient Grade 3 infusion adverse event are excluded. * Liver function test abnormality: * AST or ALT \> 5 x ULN * Total bilirubin \> 3 x ULN * Concurrent AST or ALT \> 3 x ULN and total bilirubin \> 2 x ULN * Drug related AE requiring treatment interruption for more than 2 weeks
Phase II Part 1: Overall Response Rate (ORR) by RECIST 1.1
时间窗: From treatment start, every 6 weeks for the first 9 months, then every 12 weeks up to 2 years.
Percentage of participants whose best overall response is either a Complete Response or a Partial Response according to Response Evaluation Criteria In Solid Tumors (RECIST v1.0) criteria over the the total number of evaluable participants. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.", or similar definition that is accurate and appropriate.
Phase II Part 2 Cohort A: Progression Free Survival (PFS) by RECIST 1.1
时间窗: From randomization: Every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 1 year.
PFS is defined as the time from the date of randomization to the date of first documented tumor progression or death due to any cause, whichever occurs first. If a participant has not had a PFS event at the cut-off date for analysis or at the date when a further antineoplastic therapy (other than those planned as study treatment in the protocol) is started, PFS will be censored at the date of last evaluable tumor assessment before the cut-off or start of further antineoplastic therapy.
Progression Free Survival (PFS) Phase II Part 2 Cohort A by Stratification
时间窗: From randomization: Every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 1 year.
PFS is defined as the time from the date of randomization to the date of first documented tumor progression or death due to any cause, whichever occurs first. If a participant has not had a PFS event at the cut-off date for analysis or at the date when a further antineoplastic therapy (other than those planned as study treatment in the protocol) is started, PFS will be censored at the date of last evaluable tumor assessment before the cut-off or start of further antineoplastic therapy.
次要结局
- Overall Response Rate (ORR) by Using RECIST 1.1 : Phase Ib, Phase II Part 2 Cohort A(From treatment start (phase Ib) / randomization (phase II part 2) : Every 6 weeks for the first 9 months, then every 12 weeks up to 2 years.)
- Progression Free Survival (PFS) (Phase Ib, Phase II Part 1)(From treatment start (phase Ib, phase II part 1): Every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 1 year.)
- Overall Survival (OS) : Phase Ib, Phase II Part 1, Phase II Part 2 Cohort A(From treatment start : Phase Ib, Phase II part 1 / from randomization: Phase II part 2 Cohort A through study completion, for an average of 4.5 years.)
- Duration of Overall Response (DoR): Phase Ib, Phase II Part 1, Phase II Part 2 Cohort A(From treatment start Phase Ib, Phase II part 1 / from randomization Phase II part 2 Cohort A : every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 2.5 years.)
- Proportion of Progressive Disease Phase II Part 2 Cohort B(From randomization: every 6 weeks up to 24 weeks.)